Publication

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

Bady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang-Xuan, K., Vauleon, E., Gijtenbeek, A., Enting, R., Thiessen, B., Chinot, O., Dhermain, F., Brandes, A. A., Reijneveld, J. C., Marosi, C., Taphoorn, M. J. B., Wick, W., von Deimling, A., French, P., Stupp, R., Baumert, B. G. & Hegi, M. E., Apr-2018, In : Acta Neuropathologica. 135, 4, p. 601-615 15 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Pierre Bady
  • Sebastian Kurscheid
  • Mauro Delorenzi
  • Thierry Gorlia
  • Martin J. van den Bent
  • Khe Hoang-Xuan
  • Elodie Vauleon
  • Anja Gijtenbeek
  • Roelien Enting
  • Brian Thiessen
  • Olivier Chinot
  • Frederic Dhermain
  • Alba A. Brandes
  • Jaap C. Reijneveld
  • Christine Marosi
  • Martin J. B. Taphoorn
  • Wolfgang Wick
  • Andreas von Deimling
  • Pim French
  • Roger Stupp
  • Brigitta G. Baumert
  • Monika E. Hegi

The optimal treatment for patients with low-grade glioma (LGG) WHO grade II remains controversial. Overall survival ranges from 2 to over 15 years depending on molecular and clinical factors. Hence, risk-adjusted treatments are required for optimizing outcome and quality of life. We aim at identifying mechanisms and associated molecular markers predictive for benefit from radiotherapy (RT) or temozolomide (TMZ) in LGG patients treated in the randomized phase III trial EORTC 22033. As candidate biomarkers for these genotoxic treatments, we considered the DNA methylome of 410 DNA damage response (DDR) genes. We first identified 62 functionally relevant CpG sites located in the promoters of 24 DDR genes, using the LGG data from The Cancer Genome Atlas. Then we tested their association with outcome [progression-free survival (PFS)] depending on treatment in 120 LGG patients of EORTC 22033, whose tumors were mutant for isocitrate dehydrogenase 1 or 2 (IDHmt), the molecular hallmark of LGG. The results suggested that seven CpGs of four DDR genes may be predictive for longer PFS in one of the treatment arms that comprised MGMT, MLH3, RAD21, and SMC4. Most interestingly, the two CpGs identified for MGMT are the same, previously selected for the MGMT-STP27 score that is used to determine the methylation status of the MGMT gene. This score was higher in the LGG with 1p/19q codeletion, in this and other independent LGG datasets. It was predictive for PFS in the TMZ, but not in the RT arm of EORTC 22033. The results support the hypothesis that a high score predicts benefit from TMZ treatment for patients with IDHmt LGG, regardless of the 1p/19q status. This MGMT methylation score may identify patients who benefit from first-line treatment with TMZ, to defer RT for long-term preservation of cognitive function and quality of life.

Original languageEnglish
Pages (from-to)601-615
Number of pages15
JournalActa Neuropathologica
Volume135
Issue number4
Publication statusPublished - Apr-2018

    Keywords

  • Low-grade glioma, DNA methylation, TMZ, DDR genes, MGMT-STP27, Randomized trial, MISMATCH REPAIR, METHYLATION, GLIOBLASTOMA, EXPRESSION, MGMT, TEMOZOLOMIDE, TUMORS, CELLS, RADIOTHERAPY, SENSITIVITY

Download statistics

No data available

ID: 65137301